| Nome |
# |
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-eb0b-7715-e053-1705fe0a6cc9
|
374
|
|
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries, file e1dcb338-4cfc-7715-e053-1705fe0a6cc9
|
164
|
|
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia, file e1dcb32e-d7b1-7715-e053-1705fe0a6cc9
|
119
|
|
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e1dcb334-9623-7715-e053-1705fe0a6cc9
|
117
|
|
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy, file e1dcb32c-3019-7715-e053-1705fe0a6cc9
|
114
|
|
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia., file e1dcb331-305c-7715-e053-1705fe0a6cc9
|
101
|
|
A risk prediction score for invasive mold disease in patients with hematological malignancies, file e1dcb32d-991b-7715-e053-1705fe0a6cc9
|
94
|
|
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants, file e1dcb32e-cb30-7715-e053-1705fe0a6cc9
|
90
|
|
Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?, file e1dcb332-6940-7715-e053-1705fe0a6cc9
|
89
|
|
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency, file e1dcb333-614a-7715-e053-1705fe0a6cc9
|
86
|
|
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells., file e1dcb335-162c-7715-e053-1705fe0a6cc9
|
75
|
|
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment, file e1dcb334-e5ae-7715-e053-1705fe0a6cc9
|
67
|
|
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia, file e1dcb330-4aea-7715-e053-1705fe0a6cc9
|
66
|
|
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party, file e1dcb32e-db9b-7715-e053-1705fe0a6cc9
|
60
|
|
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients., file e1dcb32e-cf5e-7715-e053-1705fe0a6cc9
|
58
|
|
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results., file e1dcb32e-d8c2-7715-e053-1705fe0a6cc9
|
53
|
|
Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives, file e1dcb336-7161-7715-e053-1705fe0a6cc9
|
52
|
|
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia, file 28c3b0be-1b08-4d0e-bd03-e2c9e8d48222
|
46
|
|
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts, file e1dcb331-8377-7715-e053-1705fe0a6cc9
|
40
|
|
Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor, file e1dcb32c-daa4-7715-e053-1705fe0a6cc9
|
26
|
|
Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives, file e1dcb330-e662-7715-e053-1705fe0a6cc9
|
18
|
|
Soft tissue and skeletal involvement in FIP1L1-PDGFR-A positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission, file e1dcb331-7e8a-7715-e053-1705fe0a6cc9
|
17
|
|
Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells., file e1dcb335-4eac-7715-e053-1705fe0a6cc9
|
15
|
|
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia, file e1dcb337-384e-7715-e053-1705fe0a6cc9
|
14
|
|
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia, file e1dcb335-14cf-7715-e053-1705fe0a6cc9
|
12
|
|
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance, file e1dcb32e-de65-7715-e053-1705fe0a6cc9
|
11
|
|
Current treatment approaches in CML., file facd034c-5d4b-4e46-9b04-3fea2a5d765b
|
11
|
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia, file e1dcb336-c3f5-7715-e053-1705fe0a6cc9
|
8
|
|
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia, file 0b6db5c0-d440-485e-9f6b-321718215366
|
7
|
|
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR), file e1dcb330-ea71-7715-e053-1705fe0a6cc9
|
7
|
|
Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly, file e1dcb331-8375-7715-e053-1705fe0a6cc9
|
7
|
|
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study, file 5b5f72b2-5339-4c53-9af8-17aade66cdc0
|
6
|
|
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia, file e1dcb32c-daa1-7715-e053-1705fe0a6cc9
|
6
|
|
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party, file e1dcb335-4eb0-7715-e053-1705fe0a6cc9
|
6
|
|
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia, file e1dcb336-df0c-7715-e053-1705fe0a6cc9
|
6
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-e3fc-7715-e053-1705fe0a6cc9
|
6
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-e3fd-7715-e053-1705fe0a6cc9
|
6
|
|
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study, file c1380f92-fec3-4a23-ae61-d2ae037435e2
|
5
|
|
Long-term outcomes of imatinib treatment for chronic myeloid leukemia, file e1dcb331-0b06-7715-e053-1705fe0a6cc9
|
5
|
|
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study, file 90453892-ecd7-4dce-9c53-c671f76120c9
|
4
|
|
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States, file e1dcb32f-accc-7715-e053-1705fe0a6cc9
|
4
|
|
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy, file e1dcb330-c14f-7715-e053-1705fe0a6cc9
|
4
|
|
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP, file e1dcb333-f43f-7715-e053-1705fe0a6cc9
|
4
|
|
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients, file e1dcb32e-e051-7715-e053-1705fe0a6cc9
|
3
|
|
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network, file 5828df37-d362-4cb1-9570-094065a30847
|
2
|
|
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia, file dbb40281-cb7f-4a69-992f-c9bbaa909228
|
2
|
|
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients., file e1dcb32e-0dd6-7715-e053-1705fe0a6cc9
|
2
|
|
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients., file e1dcb32e-e3a9-7715-e053-1705fe0a6cc9
|
2
|
|
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results, file e1dcb32c-1289-7715-e053-1705fe0a6cc9
|
1
|
|
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection., file e1dcb32c-15eb-7715-e053-1705fe0a6cc9
|
1
|
|
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies, file e1dcb32c-353b-7715-e053-1705fe0a6cc9
|
1
|
|
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE
AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK
MYELODYSPLASTIC SYNDROMES, file e1dcb32c-6c35-7715-e053-1705fe0a6cc9
|
1
|
|
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells, file e1dcb32d-34f9-7715-e053-1705fe0a6cc9
|
1
|
|
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients, file e1dcb32e-d280-7715-e053-1705fe0a6cc9
|
1
|
|
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib, file e1dcb32e-d80b-7715-e053-1705fe0a6cc9
|
1
|
|
null, file e1dcb32e-d9f4-7715-e053-1705fe0a6cc9
|
1
|
|
null, file e1dcb32e-ddc7-7715-e053-1705fe0a6cc9
|
1
|
|
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia, file e1dcb330-7faf-7715-e053-1705fe0a6cc9
|
1
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-eb0e-7715-e053-1705fe0a6cc9
|
1
|
| Totale |
2.102 |